UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy

Gagliardini, R; Gianotti, N; Maggiolo, F; Cozzi-Lepri, A; Antinori, A; Nozza, S; Lapadula, G; ... ICONA Foundation Study Group, .; + view all (2021) Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. International Journal of Antimicrobial Agents , 58 (4) , Article 106406. 10.1016/j.ijantimicag.2021.106406. Green open access

[thumbnail of Cozzi-Lepri_Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy_AAM.pdf]
Preview
Text
Cozzi-Lepri_Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy_AAM.pdf - Accepted Version

Download (307kB) | Preview

Abstract

OBJECTIVE: Comparisons between rilpivirine (RPV) and integrase strand transfer inhibitors (INSTIs) in antiretroviral therapy (ART)-naïve HIV-infected individuals are currently lacking. Aim of the study was to compare, in an observational cohort setting, the durability of treatment of RPV- and INSTI-based first-line regimens. METHODS: Patients who started first-line ARTs based on RPV or on INSTIs, with HIV-RNA <100,000 copies/mL, CD4 cells count >200 cells/μL, were included. The primary endpoint was the cumulative probability of treatment failure (TF = virological failure [confirmed HIV-RNA >50 copies/mL] or discontinuation of the anchor drug in the regimen), as assessed by Kaplan-Meier method. A multivariable Cox regression was used to control for potential confounding. RESULTS: Of 1991 patients included, 986 started ART with a RPV- and 1,005 with an INSTI-based regimen. The median (IQR) follow-up was 20 (10, 35) months. The cumulative two-years probability of TF with RPV (9.1% [95% 7.2, 11.1]) was lower than that observed in the INSTI group (16.6% [13.8, 19.4], p=0.0002) but not when comparing with dolutegravir (DTG) alone. Starting ART with an INSTIs-based regimen vs. RPV was associated with a higher risk of TF after controlling for potential confounding factors (AHR [95%CI]: 1.64 [1.28, 2.10]; p<0.001). Results were similar when restricting the analysis to STR regimens, although the probability of virological success was higher for INSTI and for DTG. CONCLUSIONS: In ART-naïve patients with low viral load and high CD4 count, the risk of treatment failure was lower in patients who started RPV- vs. INSTIs-based regimens other than DTG-based ones.

Type: Article
Title: Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ijantimicag.2021.106406
Publisher version: https://doi.org/10.1016/j.ijantimicag.2021.106406
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: antiretroviral naïve, dolutegravir, elvitegravir, raltegravir, rilpivirine, single tablet regimen
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/10132584
Downloads since deposit
62Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item